CN Patent

CN110818691A — 酮酰胺类化合物及其制备方法、药物组合物和用途

Assigned to Shanghai Institute of Materia Medica of CAS · Expires 2020-02-21 · 6y expired

What this patent protects

本发明涉及酮酰胺类化合物及其制备方法、药物组合物和用途。具体地，本发明涉及式A所示的酮酰胺类化合物、其外消旋体、对映异构体、非对映异构体或它们的混合物，或其药物活性的代谢物，或其药学上可接受的盐、溶剂化物或前药，其中各基团和取代基的定义如说明书中所述。所述化合物可有效抑制冠状病毒或埃博拉病毒，进而实现对与冠状病毒相关的疾病或者与埃博拉病毒相关的疾病的预防或治疗。

USPTO Abstract

本发明涉及酮酰胺类化合物及其制备方法、药物组合物和用途。具体地，本发明涉及式A所示的酮酰胺类化合物、其外消旋体、对映异构体、非对映异构体或它们的混合物，或其药物活性的代谢物，或其药学上可接受的盐、溶剂化物或前药，其中各基团和取代基的定义如说明书中所述。所述化合物可有效抑制冠状病毒或埃博拉病毒，进而实现对与冠状病毒相关的疾病或者与埃博拉病毒相关的疾病的预防或治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN110818691A
Jurisdiction
CN
Classification
—
Expires
2020-02-21
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Institute of Materia Medica of CAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.